Last reviewed · How we verify
TAK-079
At a glance
| Generic name | TAK-079 |
|---|---|
| Also known as | Mezagitamab |
| Sponsor | Takeda |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition (PHASE3)
- A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM) (PHASE1)
- A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia (PHASE3)
- A Continuation Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia (PHASE3)
- A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy (PHASE1)
- A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia (PHASE2)
- A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE) (PHASE1)
- A Study of TAK-079 in People With Generalized Myasthenia Gravis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TAK-079 CI brief — competitive landscape report
- TAK-079 updates RSS · CI watch RSS
- Takeda portfolio CI